Bright Minds Biosciences (NASDAQ: DRUG) ends equity distribution deal

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. reports that, on January 7, 2026, it mutually agreed with Piper Sandler & Co. and Cantor Fitzgerald & Co. to terminate their Equity Distribution Agreement dated August 25, 2025, effective the same day. This agreement had allowed the company to distribute equity through these firms, and its termination ends that arrangement.

The company also notes that this disclosure is incorporated by reference into its registration statements on Form F-3 with file numbers 333-284694 and 333-289851.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

400 N Aberdeen St Suite 900
Chicago, IL 60642
(U.S. Corporate headquarters) 1122 Mainland St #228
Vancouver, BC V6B 5L1
(Canadian Corporate headquarters)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ ]  Form 40-F [ X ]

On January 7, 2026, Bright Minds Biosciences Inc. (the "Company"), Piper Sandler & Co. ("Piper Sandler") and Cantor Fitzgerald & Co. ("Cantor") mutually agreed to terminate the Equity Distribution Agreement, dated August 25, 2025, between the Company, Piper Sandler and Cantor, effective January 7, 2026.

INCORPORATION BY REFERENCE

The disclosure in this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694) filed on February 5, 2025, and (b) registration statement on Form F-3 (File No. 333-289851) filed on August 26, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRIGHT MINDS BIOSCIENCES INC.

/s/ Ryan Cheung

Ryan Cheung

Chief Financial Officer

Date:  January 7, 2026

FAQ

What did Bright Minds Biosciences Inc. (DRUG) disclose in this Form 6-K?

Bright Minds Biosciences Inc. disclosed that it mutually agreed with Piper Sandler & Co. and Cantor Fitzgerald & Co. to terminate their Equity Distribution Agreement dated August 25, 2025, effective January 7, 2026.

Which agreement did Bright Minds Biosciences (DRUG) terminate?

Bright Minds Biosciences terminated its Equity Distribution Agreement dated August 25, 2025, with Piper Sandler & Co. and Cantor Fitzgerald & Co., effective January 7, 2026.

Was the termination of the Equity Distribution Agreement for Bright Minds (DRUG) mutual?

Yes. The Form 6-K states that Bright Minds Biosciences Inc., Piper Sandler & Co., and Cantor Fitzgerald & Co. mutually agreed to terminate the Equity Distribution Agreement.

When did the termination of Bright Minds’ Equity Distribution Agreement become effective?

The termination of the Equity Distribution Agreement among Bright Minds Biosciences Inc., Piper Sandler & Co., and Cantor Fitzgerald & Co. was effective on January 7, 2026.

How is this Bright Minds (DRUG) 6-K incorporated into other SEC filings?

The disclosure is incorporated by reference into Bright Minds Biosciences Inc.’s registration statements on Form F-3 with file numbers 333-284694 and 333-289851.

Who signed the Bright Minds Biosciences (DRUG) Form 6-K?

The Form 6-K was signed on behalf of Bright Minds Biosciences Inc. by Ryan Cheung, Chief Financial Officer, dated January 7, 2026.